Abstract: This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use these compounds, for example in a method of treatment of cardiac conditions.

Abstract: An apparatus includes a processor configured to receive, during editing of a first design, user input indicating that a first design element has a first content role. The processor is configured to generate a content signature of the first design indicating that the first design element has the first content role, to generate a second design based on a design template, and to update the second design by applying the content signature to the second design. Generating the second design includes, based on determining that the design template includes a second design element having the first content role, adding a third design element having the first content role to the second design. Applying the content signature to the second design includes transferring content from the first design element to the third design element. The processor is configured to generate a graphical user interface including an image of the second design.

Abstract: In one example in accordance with the present disclosure, an additive manufacturing system is described. The additive manufacturing system includes an additive manufacturing device to form 1) a three-dimensional (3D) printed object and a container structure to form part of the 3D printed object. The container structure expels a payload when a predetermined condition is met. The additive manufacturing system also includes a payload distributor to place the payload in the container structure. A controller of the additive manufacturing system controls formation of the 3D printed object and the container structure.

Abstract: In one example in accordance with the present disclosure, an additive manufacturing system is described. The additive manufacturing system includes an additive manufacturing device to form a three-dimensional (3D) printed object. The additive manufacturing system also includes a placement device to embed at least a portion of a container structure into the 3D printed object. The container structure expels a payload when a predetermined condition is met. A controller of the additive manufacturing system controls additive manufacturing and placement of the portion of the container structure.

Abstract: 3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies.

Abstract: In a method for producing a whey protein hydrolysate, a whey substrate, selected from the group consisting of whey, commercially available whey powder, whey protein isolate, whey protein preparations, and ?-Lactalbumin obtained from whey, is enzymatically hydrolyzing at least with alcalase and trypsin as enzymes at a ratio of g enzymes/g whey substrate between 1:10 and 1:10,000 and at a temperature of between 30° C. and 70° C. within an incubation period of between 18 hours and 30 hours, until a hydrolysis degree of more than 50% of the protein of the whey substrate have a molecular weight of less than 4 kDa. The enzymes are inactivated by heating the enzymes to a temperature of 80° C. to 100° C. after the desired hydrolysis degree has been reached.

Abstract: 3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies.

Abstract: The invention relates to a whey protein hydrolysate, in particular a hydrolysate consisting of whey protein enriched with ?-lactalbumin and ?-lactalbumin, and the use thereof for producing pharmaceuticals, anti-hypertensive agents, food supplements, foodstuffs and animal feed, and to pharmaceuticals, anti-hypertensive agents, food supplements, foodstuffs and animal feed produced in this manner. The whey protein hydrolysate according to the invention, which has an ACE inhibiting and anti-hypertensive action, contains a physiologically active quantity of at least one peptide containing tryptophan, preferably at least one of the bio-active dipeptides Ile-Trp and Trp-Leu, and can be obtained by the extensive hydrolysis of whey protein isolates or of pure ?-lactalbumin.